EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Praxis Precision Medicines's Enterprise Value is $525.49 Mil.
Praxis Precision Medicines's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-99.15 Mil. Therefore, Praxis Precision Medicines's EV-to-FCF for today is -5.30.
The historical rank and industry rank for Praxis Precision Medicines's EV-to-FCF or its related term are showing as below:
PRAX'
s EV-to-FCF Range Over the Past 10 Years
Min: -5.67 Med: -0.36 Max: 0.39
Current: -5.3
During the past 6 years, the highest EV-to-FCF of Praxis Precision Medicines was 0.39. The lowest was -5.67. And the median was -0.36.
PRAX's EV-to-FCF is ranked worse than 100% of 372
companies
in the Biotechnology industry
Industry Median: 8.36
vs PRAX: -5.30
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Praxis Precision Medicines's EV-to-FCF
For the Biotechnology subindustry, Praxis Precision Medicines's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Praxis Precision Medicines's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Praxis Precision Medicines's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Praxis Precision Medicines's EV-to-FCF falls into.
Praxis Precision Medicines's current Enterprise Value is $525.49 Mil.
Praxis Precision Medicines's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-99.15 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Praxis Precision Medicines's PE Ratio for today is calculated as:
Praxis Precision Medicines's share price for today is $44.08.
Praxis Precision Medicines's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-14.780.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Praxis Precision Medicines EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Praxis Precision Medicines's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Praxis Precision Medicines (Praxis Precision Medicines) Business Description
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PRAX has been successfully added to your 